Will PerkinElmer (PKI) Disappoint this Earnings Season?

PerkinElmer Inc.PKI is expected to report fourth-quarter 2016 results on Feb 2, 2017.

PerkinElmer's track record has been quite impressive, with the company comfortably beating estimates in three of the four trailing quarters. In the last reported quarter, it recorded a positive earnings surprise of 3.03%, bringing the four-quarter average to 3.30%. Over the past three months, PerkinElmer returned almost 2.48%, which is lower than the Zacks categorized Instruments Scientific sub-industry's gain of roughly 5.36%. However, PerkinElmer has a decent earnings surprise history, as evident from the chart below.

Factors at Play

An expanding product portfolio, margin expansion and accretive acquisitions were thekey positives for PerkinElmerin the fourth quarter. Moreover, partnerships with the likes of Sophie BioSciences, Monash Institute of Pharmacutical Sciences, Good Start Genetics and others are anticipated to drive top-line growth. Diagnostic Business is also expected to prove accretive in the to-be-reported quarter.

However, lower-than-estimated demand in the academic and government segments as well as sluggishness in the developed markets are likely to mar opportunities for PerkinElmer in the fourth quarter. Management expects revenues to represent low single-digit organic growth and areforecast in the range of $610 million to $620 million. Adjusted earnings for the quarter under discussion are projected in the range of 85 cents to 87 cents per share.

Earnings Whispers

Our proven model does not conclusively show that PerkinElmer is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.

Zacks ESP: The Earnings ESP for PerkinElmer is -1.16%. This is because the Most Accurate estimate stands at 85 cents and the Zacks Consensus Estimate is pegged at 86 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .

Zacks Rank: PerkinElmer carries a Zacks Rank #4 (Sell). We caution against stocks with a Zacks Ranks #4 or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revisions.

Stocks That Warrant a Look

Here are a few companies that you may want to consider instead, as our model shows that they have the right combination of elements to post an earnings beat this quarter:

Cempra Inc. CEMP has an Earnings ESP of +15.79% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .

Molina Healthcare Inc. MOH has an Earnings ESP of +5.33% and a Zacks Rank #2.

Universal Health Services, Inc. UHS has an Earnings ESP of +4.97% and a Zacks Rank #2.

The Best Place to Start Your Stock Search

Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research. See these stocks free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PerkinElmer, Inc. (PKI): Free Stock Analysis Report

Molina Healthcare Inc (MOH): Free Stock Analysis Report

Universal Health Services, Inc. (UHS): Free Stock Analysis Report

Cempra, Inc. (CEMP): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics

Earnings Stocks

Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More